Drug to drug interaction with NSAIDS.
Do not increased insulin secretion.
Inhibit production of glucose by the liver.
Prevents kidneys from reabsorbing glucose.
Stimulate pancreas to secrete insulin.
Enhances glucose-dependent insulin secretion.
Usually given once a day.
Increase and prolong the action of the hormone that increases insulin release and decreases glucagon levels.
Sensitize body tissue to insulin: stimulates insulin receptor sites.
Possible side-effect of impaired platelet function.
Stimulate beta cells of the pancreas.
Glucagon-like peptide-1 agonist (liraglutide/Victoza,, dulaglutide/Trulicity)
Alpha-glucosidase inhibitors (acarbose/Precose, miglitol (Glyset)
Sodium-glucose co-transporter 2 inhibitors (empagliflozin/Jardiance
Avandia
Dipeptidyl Pepidase-4 Inhibitors (sitagliptin/Januvia, vildagliptin /Galvus)
Non-sulfonylurea insulin secretagogues (repaglinide/Prandin, nateglinide/Starlix)
Biguanides (metformin (Glucophage) Metformin with glyburide (Glucovance)
Thiazolidinediones (pioglitazone (actos, rosiglitazone/Avandia)
Second generation sulfonylureas (glipizide (Glucotrol) Glyburide (DiaBeta) Glimepiride (Amaryl)
glipizide
Januvia
